Annotation of sequence variants in cancer samples: Processes and pitfalls for routine assays in the clinical laboratory

Journal of Molecular Diagnostics

Volumn 17, Issue 4, 2015, Pages 339-351

  Lee, Lobin A ^a   Arvai, Kevin J ^a   Jones, Dan ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; BAYESIAN LEARNING; BIOASSAY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CLINICAL LABORATORY; DNA SEQUENCE; GENE SEQUENCE; GENETIC DIFFERENCE; GENETIC VARIABILITY; GERMLINE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; METHODOLOGY; MINIMAL RESIDUAL DISEASE; NONHUMAN; REVIEW; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TISSUE SECTION; TREATMENT RESPONSE; TUMOR GENE; DIAGNOSTIC TEST; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN GENOME; LABORATORY DIAGNOSIS; MOLECULAR GENETICS; NEOPLASMS; PROCEDURES; TRENDS;

CLINICAL LABORATORY SERVICES; DIAGNOSTIC TESTS, ROUTINE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOME, HUMAN; HUMANS; MOLECULAR SEQUENCE ANNOTATION; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84931397162     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2015.03.003     Document Type: Review

References (75)

1. M.C. King, J.H. Marks, and J.B. Mandell Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 2003 643 646
2. H.T. Lynch, and A. de la Chapelle Genetic susceptibility to non-polyposis colorectal cancer J Med Genet 36 1999 801 818
3. Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls Nature 447 2007 661 678
4. T.A. Manolio, F.S. Collins, N.J. Cox, D.B. Goldstein, L.A. Hindorff, D.J. Hunter, M.I. McCarthy, E.M. Ramos, L.R. Cardon, A. Chakravarti, J.H. Cho, A.E. Guttmacher, A. Kong, L. Kruglyak, E. Mardis, C.N. Rotimi, M. Slatkin, D. Valle, A.S. Whittemore, M. Boehnke, A.G. Clark, E.E. Eichler, G. Gibson, J.L. Haines, T.F. Mackay, S.A. McCarroll, and P.M. Visscher Finding the missing heritability of complex diseases Nature 461 2009 747 753
5. L.M. Dong, J.D. Potter, E. White, C.M. Ulrich, L.R. Cardon, and U. Peters Genetic susceptibility to cancer: the role of polymorphisms in candidate genes JAMA 299 2008 2423 2436
6. J. McClellan, and M.C. King Genetic heterogeneity in human disease Cell 141 2010 210 217
7. D.E. Larson, C.C. Harris, K. Chen, D.C. Koboldt, T.E. Abbott, D.J. Dooling, T.J. Ley, E.R. Mardis, R.K. Wilson, and L. Ding SomaticSniper: identification of somatic point mutations in whole genome sequencing data Bioinformatics 28 2012 311 317
8. N. Aziz, Q. Zhao, L. Bry, D.K. Driscoll, B. Funke, J.S. Gibson, W.W. Grody, M.R. Hegde, G.A. Hoeltge, D.G.B. Leonard, J.D. Merker, R. Nagarajan, L.A. Palicki, R.S. Robetorye, I. Schrijver, K.E. Weck, and K.V. Voelkerding College of American Pathologists' laboratory standards for next-generation sequencing clinical tests Arch Pathol Lab Med 139 2015 481 493
9. The International HapMap Project Nature 426 2003 789 796
10. J.A. Tennessen, A.W. Bigham, T.D. O'Connor, W. Fu, E.E. Kenny, S. Gravel, S. McGee, R. Do, X. Liu, G. Jun, H.M. Kang, D. Jordan, S.M. Leal, S. Gabriel, M.J. Rieder, G. Abecasis, D. Altshuler, D.A. Nickerson, E. Boerwinkle, S. Sunyaev, C.D. Bustamante, M.J. Bamshad, and J.M. Akey Evolution and functional impact of rare coding variation from deep sequencing of human exomes Science 337 2012 64 69
11. G.R. Abecasis, A. Auton, L.D. Brooks, M.A. DePristo, R.M. Durbin, R.E. Handsaker, H.M. Kang, G.T. Marth, and G.A. McVean An integrated map of genetic variation from 1,092 human genomes Nature 491 2012 56 65
12. T.P. Yang, C. Beazley, S.B. Montgomery, A.S. Dimas, M. Gutierrez-Arcelus, B.E. Stranger, P. Deloukas, and E.T. Dermitzakis Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies Bioinformatics 26 2010 2474 2476
13. Database resources of the National Center for Biotechnology Information Nucleic Acids Res 42 2014 D7 D17
14. J.R. MacDonald, R. Ziman, R.K. Yuen, L. Feuk, and S.W. Scherer The Database of Genomic Variants: a curated collection of structural variation in the human genome Nucleic Acids Res 42 2014 D986 D992
15. I.P. Gorlov, O.Y. Gorlova, S.R. Sunyaev, M.R. Spitz, and C.I. Amos Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms Am J Hum Genet 82 2008 100 112
16. G.R. Abecasis, D. Altshuler, A. Auton, L.D. Brooks, R.M. Durbin, R.A. Gibbs, M.E. Hurles, and G.A. McVean A map of human genome variation from population-scale sequencing Nature 467 2010 1061 1073
17. M.J. Landrum, J.M. Lee, G.R. Riley, W. Jang, W.S. Rubinstein, D.M. Church, and D.R. Maglott ClinVar: public archive of relationships among sequence variation and human phenotype Nucleic Acids Res 42 2014 D980 D985
18. C.S. Richards, S. Bale, D.B. Bellissimo, S. Das, W.W. Grody, M.R. Hegde, E. Lyon, and B.E. Ward ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007 Genet Med 10 2008 294 300
19. S.V. Tavtigian, M.S. Greenblatt, D.E. Goldgar, and P. Boffetta Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group Hum Mutat 29 2008 1261 1264
20. D.E. Goldgar, D.F. Easton, A.M. Deffenbaugh, A.N. Monteiro, S.V. Tavtigian, and F.J. Couch Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2 Am J Hum Genet 75 2004 535 544
21. B.A. Thompson, A.B. Spurdle, J.P. Plazzer, M.S. Greenblatt, K. Akagi, and F. Al-Mulla Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database Nat Genet 46 2014 107 115
22. D.F. Easton, A.M. Deffenbaugh, D. Pruss, C. Frye, R.J. Wenstrup, K. Allen-Brady, S.V. Tavtigian, A.N. Monteiro, E.S. Iversen, F.J. Couch, and D.E. Goldgar A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes Am J Hum Genet 81 2007 873 883
23. M. Greaves, and C.C. Maley Clonal evolution in cancer Nature 481 2012 306 313
24. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, S. Begum, N.Q. McDonald, A. Butler, D. Jones, K. Raine, C. Latimer, C.R. Santos, M. Nohadani, A.C. Eklund, B. Spencer-Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P.A. Futreal, and C. Swanton Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
25. Q. Qi, Y. Liu, Y. Cheng, J. Glanville, D. Zhang, J.Y. Lee, R.A. Olshen, C.M. Weyand, S.D. Boyd, and J.J. Goronzy Diversity and clonal selection in the human T-cell repertoire Proc Natl Acad Sci U S A 111 2014 13139 13144
26. J.A. Schumacher, E.J. Duncavage, T.L. Mosbruger, P.M. Szankasi, and T.W. Kelley A comparison of deep sequencing of TCRG rearrangements vs traditional capillary electrophoresis for assessment of clonality in T-cell lymphoproliferative disorders Am J Clin Pathol 141 2014 348 359
27. L.A. Lee, Y. Wang, R. Maiese, K.J. Arvai, Q. Pan, K. Mehta, S.M. Caruthers, S.L. Gersen, S. Billouin-Frazier, F.K. Racke, and D. Jones Assessment of mutation status in a large series of patients with suspected cytopenias with normal karyotypes and without increased blasts [abstract] Blood 124 2014 4606
28. J.V. Lacey Jr., G.L. Mutter, M.R. Nucci, B.M. Ronnett, O.B. Ioffe, B.B. Rush, A.G. Glass, D.A. Richesson, N. Chatterjee, B. Langholz, and M.E. Sherman Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies Cancer 113 2008 2073 2081
29. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N Engl J Med 368 2013 2059 2074
30. N. Cervera, R. Itzykson, E. Coppin, T. Prebet, A. Murati, S. Legall, N. Vey, E. Solary, D. Birnbaum, and V. Gelsi-Boyer Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia Am J Hematol 89 2014 604 609
31. M.M. Patnaik, E. Padron, R.R. Laborde, T.L. Lasho, C.M. Finke, C.A. Hanson, J.M. Hodnefield, R.A. Knudson, R.P. Ketterling, A. Al-Kali, A. Pardanani, N.A. Ali, R.S. Komrokji, and A. Tefferi Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes Leukemia 27 2013 1504 1510
32. S. Schnittger, U. Bacher, C. Eder, F. Dicker, T. Alpermann, V. Grossmann, A. Kohlmann, W. Kern, C. Haferlach, and T. Haferlach Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow Haematologica 97 2012 1582 1585
33. C. Kandoth, N. Schultz, A.D. Cherniack, R. Akbani, Y. Liu, H. Shen, A.G. Robertson, I. Pashtan, R. Shen, C.C. Benz, C. Yau, P.W. Laird, L. Ding, W. Zhang, G.B. Mills, R. Kucherlapati, E.R. Mardis, and D.A. Levine Integrated genomic characterization of endometrial carcinoma Nature 497 2013 67 73
34. R.W. Tothill, J. Li, L. Mileshkin, K. Doig, T. Siganakis, P. Cowin, A. Fellowes, T. Semple, S. Fox, K. Byron, A. Kowalczyk, D. Thomas, P. Schofield, and D.D. Bowtell Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary J Pathol 231 2013 413 423
35. J.W. Vardiman, J. Thiele, D.A. Arber, R.D. Brunning, M.J. Borowitz, A. Porwit, N.L. Harris, M.M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, and C.D. Bloomfield The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
36. A. Fasan, T. Alpermann, C. Haferlach, V. Grossmann, A. Roller, A. Kohlmann, C. Eder, W. Kern, T. Haferlach, and S. Schnittger Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases PLoS One 8 2013 e54365
37. E. Jabbour, D. Jones, H.M. Kantarjian, S. O'Brien, C. Tam, C. Koller, J.A. Burger, G. Borthakur, W.G. Wierda, and J. Cortes Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations Blood 114 2009 2037 2043
38. T. Mok, J.J. Yang, and K.C. Lam Treating patients with EGFR-sensitizing mutations: first line or second line-is there a difference? J Clin Oncol 31 2013 1081 1088
39. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S.J. O'Day, J.A. Sosman, J.M. Kirkwood, A.M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty, and G.A. McArthur Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
40. N. Puig, M.E. Sarasquete, A. Balanzategui, J. Martinez, B. Paiva, H. Garcia, S. Fumero, C. Jimenez, M. Alcoceba, M.C. Chillon, E. Sebastian, L. Marin, M.A. Montalban, M.V. Mateos, A. Oriol, L. Palomera, J. de la Rubia, M.B. Vidriales, J. Blade, J.J. Lahuerta, M. Gonzalez, J.F. Miguel, and R. Garcia-Sanz Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma: a comparative analysis with flow cytometry Leukemia 28 2014 391 397
41. D. Wu, A. Sherwood, J.R. Fromm, S.S. Winter, K.P. Dunsmore, M.L. Loh, H.A. Greisman, D.E. Sabath, B.L. Wood, and H. Robins High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia Sci Transl Med 4 2012 134ra63
42. L.F. Stead, K.M. Sutton, G.R. Taylor, P. Quirke, and P. Rabbitts Accurately identifying low-allelic fraction variants in single samples with next-generation sequencing: applications in tumor subclone resolution Hum Mutat 34 2013 1432 1438
43. K. Chen, F. Meric-Bernstam, H. Zhao, Q. Zhang, N. Ezzeddine, L.Y. Tang, Y. Qi, Y. Mao, T. Chen, Z. Chong, W. Zhou, X. Zheng, A. Johnson, K.D. Aldape, M.J. Routbort, R. Luthra, S. Kopetz, M.A. Davies, J. de Groot, S. Moulder, R. Vinod, C.J. Farhangfar, K.M. Shaw, J. Mendelsohn, G.B. Mills, and A.K. Eterovic Clinical actionability enhanced through deep targeted sequencing of solid tumors Clin Chem 61 2015 544 553
44. C.C. Lin, H.A. Hou, W.C. Chou, Y.Y. Kuo, C.Y. Liu, C.Y. Chen, Y.J. Lai, M.H. Tseng, C.F. Huang, Y.C. Chiang, F.Y. Lee, M.C. Liu, C.W. Liu, J.L. Tang, M. Yao, S.Y. Huang, B.S. Ko, S.J. Wu, W. Tsay, Y.C. Chen, and H.F. Tien IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution Am J Hematol 89 2014 137 144
45. R. Daber, S. Sukhadia, and J.J. Morrissette Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets Cancer Genet 206 2013 441 448
46. D.H. Spencer, H.J. Abel, C.M. Lockwood, J.E. Payton, P. Szankasi, T.W. Kelley, S. Kulkarni, J.D. Pfeifer, and E.J. Duncavage Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data J Mol Diagn 15 2013 81 93
47. S.A. Forbes, N. Bindal, S. Bamford, C. Cole, C.Y. Kok, D. Beare, M. Jia, R. Shepherd, K. Leung, A. Menzies, J.W. Teague, P.J. Campbell, M.R. Stratton, and P.A. Futreal COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res 39 2011 D945 D950
48. D.W. Bell, I. Gore, R.A. Okimoto, N. Godin-Heymann, R. Sordella, R. Mulloy, S.V. Sharma, B.W. Brannigan, G. Mohapatra, J. Settleman, and D.A. Haber Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR Nat Genet 37 2005 1315 1316
49. K.H. Metzeler, K. Maharry, M.D. Radmacher, K. Mrozek, D. Margeson, H. Becker, J. Curfman, K.B. Holland, S. Schwind, S.P. Whitman, Y.Z. Wu, W. Blum, B.L. Powell, T.H. Carter, M. Wetzler, J.O. Moore, J.E. Kolitz, M.R. Baer, A.J. Carroll, R.A. Larson, M.A. Caligiuri, G. Marcucci, and C.D. Bloomfield TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study J Clin Oncol 29 2011 1373 1381
50. P.L. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-Manero, F. Sole, J.M. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, A. Levis, L. Malcovati, M. Cazzola, J. Cermak, C. Fonatsch, M.M. Le Beau, M.L. Slovak, O. Krieger, M. Luebbert, J. Maciejewski, S.M. Magalhaes, Y. Miyazaki, M. Pfeilstocker, M. Sekeres, W.R. Sperr, R. Stauder, S. Tauro, P. Valent, T. Vallespi, A.A. van de Loosdrecht, U. Germing, and D. Haase Revised international prognostic scoring system for myelodysplastic syndromes Blood 120 2012 2454 2465
51. L. Malcovati, E. Hellstrom-Lindberg, D. Bowen, L. Ades, J. Cermak, C.C. Del, M.G. Della Porta, P. Fenaux, N. Gattermann, U. Germing, J.H. Jansen, M. Mittelman, G. Mufti, U. Platzbecker, G.F. Sanz, D. Selleslag, M. Skov-Holm, R. Stauder, A. Symeonidis, A.A. van de Loosdrecht, W.T. de, and M. Cazzola Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Blood 122 2013 2943 2964
52. E. Solary, O.A. Bernard, A. Tefferi, F. Fuks, and W. Vainchenker The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases Leukemia 28 2014 485 496
53. M. Ko, Y. Huang, A.M. Jankowska, U.J. Pape, M. Tahiliani, H.S. Bandukwala, J. An, E.D. Lamperti, K.P. Koh, R. Ganetzky, X.S. Liu, L. Aravind, S. Agarwal, J.P. Maciejewski, and A. Rao Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 Nature 468 2010 839 843
54. G. Genovese, A.K. Kähler, R.E. Handsaker, J. Lindberg, S.A. Rose, S.F. Bakhoum, K. Chambert, E. Mick, B.M. Neale, M. Fromer, S.M. Purcell, O. Svantesson, M. Landén, M. Höglund, S. Lehmann, S.B. Gabriel, J.L. Moran, E.S. Lander, P.F. Sullivan, P. Sklar, H. Grönberg, C.M. Hultman, and S.A. McCarroll Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence N Engl J Med 371 2014 2477 2487
55. V.I. Gaidzik, P. Paschka, D. Spath, M. Habdank, C.H. Kohne, U. Germing, M. von Lilienfeld-Toal, G. Held, H.A. Horst, D. Haase, M. Bentz, K. Gotze, H. Dohner, R.F. Schlenk, L. Bullinger, and K. Dohner TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group J Clin Oncol 30 2012 1350 1357
56. A.E. Smith, A.M. Mohamedali, A. Kulasekararaj, Z. Lim, J. Gaken, N.C. Lea, B. Przychodzen, S.A. Mian, E.E. Nasser, C. Shooter, N.B. Westwood, C. Strupp, N. Gattermann, J.P. Maciejewski, U. Germing, and G.J. Mufti Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value Blood 116 2010 3923 3932
57. L. Hu, Z. Li, J. Cheng, Q. Rao, W. Gong, M. Liu, Y.G. Shi, J. Zhu, P. Wang, and Y. Xu Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation Cell 155 2013 1545 1555
58. T.L. Lin, Y. Nagata, H.W. Kao, M. Sanada, Y. Okuno, C.F. Huang, D.C. Liang, M.C. Kuo, C.L. Lai, E.H. Lee, Y.S. Shih, H. Tanaka, Y. Shiraishi, K. Chiba, T.H. Lin, J.H. Wu, S. Miyano, S. Ogawa, and L.Y. Shih Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations Haematologica 99 2014 28 36
59. O. Nibourel, O. Kosmider, M. Cheok, N. Boissel, A. Renneville, N. Philippe, H. Dombret, F. Dreyfus, B. Quesnel, S. Geffroy, S. Quentin, C. Roche-Lestienne, J.M. Cayuela, C. Roumier, P. Fenaux, W. Vainchenker, O.A. Bernard, J. Soulier, M. Fontenay, and C. Preudhomme Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission Blood 116 2010 1132 1135
60. S.V. Tavtigian, M.S. Greenblatt, F. Lesueur, and G.B. Byrnes In silico analysis of missense substitutions using sequence-alignment based methods Hum Mutat 29 2008 1327 1336
61. P.A. Chan, S. Duraisamy, P.J. Miller, J.A. Newell, C. McBride, J.P. Bond, T. Raevaara, S. Ollila, M. Nyström, A.J. Grimm, J. Christodoulou, W.S. Oetting, and M.S. Greenblatt Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR) Hum Mutat 28 2007 683 693
62. B. Gemovic, V. Perovic, S. Glisic, and N. Veljkovic Feature-based classification of amino acid substitutions outside conserved functional protein domains Scientific World Journal 2013 2013 948617
63. A. Gonzalez-Perez, and N. Lopez-Bigas Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel Am J Hum Genet 88 2011 440 449
64. L.I. Kroeze, M.G. Aslanyan, R.A. van, T.N. Koorenhof-Scheele, M. Massop, T. Carell, J.B. Boezeman, J.P. Marie, C.J. Halkes, W.T. de, G. Huls, S. Suciu, R.A. Wevers, B.A. van der Reijden, and J.H. Jansen Characterization of acute myeloid leukemia based on levels of global hydroxymethylation Blood 124 2014 1110 1118
65. M.S. Lawrence, P. Stojanov, P. Polak, G.V. Kryukov, K. Cibulskis, and A. Sivachenko Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature 499 2013 214 218
66. S. Weissmann, T. Alpermann, V. Grossmann, A. Kowarsch, N. Nadarajah, C. Eder, F. Dicker, A. Fasan, C. Haferlach, T. Haferlach, W. Kern, S. Schnittger, and A. Kohlmann Landscape of TET2 mutations in acute myeloid leukemia Leukemia 26 2012 934 942
67. M.A. Kutny, T.A. Alonzo, R.B. Gerbing, P.A. Ho, D. Geraghty, B. Lange, N.A. Heerema, and S. Meshinchi TET2 SNP rs2454206 (I1762V) correlates with improved survival in pediatric acute myelogenous leukemia, a report from the Children's Oncology Group [abstract] Blood 116 2010 418a
68. N.M. Lindor, L. Guidugli, X. Wang, M.P. Vallee, A.N. Monteiro, S. Tavtigian, D.E. Goldgar, and F.J. Couch A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) Hum Mutat 33 2012 8 21
69. G.A. McArthur, P.B. Chapman, C. Robert, J. Larkin, J.B. Haanen, R. Dummer, A. Ribas, D. Hogg, O. Hamid, P.A. Ascierto, C. Garbe, A. Testori, M. Maio, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, S.J. O'Day, J.M. Kirkwood, A.M. Eggermont, B. Dreno, J.A. Sosman, K.T. Flaherty, M. Yin, I. Caro, S. Cheng, K. Trunzer, and A. Hauschild Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Lancet Oncol 15 2014 323 332
70. P.B. Landsman-Blumberg, G.C. Carter, B.H. Johnson, R. Sedgley, S.J. Nicol, L. Li, and V. Shankaran Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. community-based oncology practices Clin Colorectal Cancer 13 2014 178 184
71. K. Qu, Q. Pan, X. Zhang, L. Rodriguez, K. Zhang, H. Li, A. Ho, H. Sanders, A. Sferruzza, S.M. Cheng, D. Nguyen, D. Jones, and F. Waldman Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays J Mol Diagn 15 2013 790 795
72. D. Ding, Y. Yu, Z. Li, X. Niu, and S. Lu The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis Onco Targets Ther 7 2014 387 393
73. H.A. Bradeen, C.A. Eide, T. O'Hare, K.J. Johnson, S.G. Willis, F.Y. Lee, B.J. Druker, and M.W. Deininger Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations Blood 108 2006 2332 2338
74. C.E. Cottrell, H. Al-Kateb, A.J. Bredemeyer, E.J. Duncavage, D.H. Spencer, H.J. Abel, C.M. Lockwood, I.S. Hagemann, S.M. O'Guin, L.C. Burcea, C.S. Sawyer, D.M. Oschwald, J.L. Stratman, D.A. Sher, M.R. Johnson, J.T. Brown, P.F. Cliften, B. George, L.D. McIntosh, S. Shrivastava, T.T. Nguyen, J.E. Payton, M.A. Watson, S.D. Crosby, R.D. Head, R.D. Mitra, R. Nagarajan, S. Kulkarni, K. Seibert, H.W. Virgin, J. Milbrandt, and J.D. Pfeifer Validation of a next-generation sequencing assay for clinical molecular oncology J Mol Diagn 16 2014 89 105
75. H. Jung, T. Bleazard, J. Lee, and D. Hong Systematic investigation of cancer-associated somatic point mutations in SNP databases Nat Biotechnol 31 2013 787 789